Literature DB >> 12694550

Three years of haemovigilance in a general university hospital.

C Michlig1, D-H Vu, J-B Wasserfallen, D R Spahn, P Schneider, J-D Tissot.   

Abstract

The aim of this study is to describe a newly implemented haemovigilance system in a general university hospital. We present a series of short cases, highlighting particular aspects of the reports, and an overview of all reported incidents between 1999 and 2001. Incidents related to transfusion of blood products were reported by the clinicians using a standard preformatted form, giving a synopsis of the incident. After analysis, we distinguished, on the one hand, transfusion reactions, that are transfusions which engendered signs or symptoms, and, on the other hand, the incidents where management errors and/or dysfunctions took place. Over 3 years, 233 incidents were reported, corresponding to 4.2 events for 1000 blood products delivered. Of the 233, 198 (85%) were acute transfusion reactions and 35 (15%) were management errors and/or dysfunctions. Platelet units gave rise to statistically (P < 0.001) more transfusion reactions (10.7 per thousand ) than red blood cells (3.5 per thousand ) and fresh frozen plasma (0.8 per thousand ), particularly febrile nonhaemolytic transfusion reactions and allergic reactions. A detailed analysis of some of the transfusion incident reports revealed complex deviations and/or failures of the procedures in place in the hospital, allowing the implementation of corrective and preventive measures. Thus, the haemovigilance system in place in the 'Centre Hospitalier Universitaire Vaudois, CHUV' appears to constitute an excellent instrument for monitoring the security of blood transfusion.

Entities:  

Mesh:

Year:  2003        PMID: 12694550     DOI: 10.1046/j.1365-3148.2003.00421.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  8 in total

1.  Swiss Haemovigilance Data and Implementation of Measures for the Prevention of Transfusion Associated Acute Lung Injury (TRALI).

Authors:  Markus Jutzi; Guy Levy; Behrouz Mansouri Taleghani
Journal:  Transfus Med Hemother       Date:  2008-03-17       Impact factor: 3.747

2.  A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery--the APAP trial (ISRCTN45810007).

Authors:  D Antolovic; A Rakow; P Contin; A Ulrich; N N Rahbari; M W Büchler; J Weitz; M Koch
Journal:  Langenbecks Arch Surg       Date:  2011-11-03       Impact factor: 3.445

Review 3.  How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery.

Authors:  Helge Möllmann; Holger M Nef; Christian W Hamm; Albrecht Elsässer
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

4.  Analysis of immediate transfusion incidents reported in a regional blood bank.

Authors:  Adriana Lemos de Sousa Neto; Maria Helena Barbosa
Journal:  Rev Bras Hematol Hemoter       Date:  2011

5.  Perioperative handling of patients on antiplatelet therapy with need for surgery.

Authors:  Matteo Nicola Dario Di Minno; Domenico Prisco; Anna Lilia Ruocco; Pasquale Mastronardi; Salvatore Massa; Giovanni Di Minno
Journal:  Intern Emerg Med       Date:  2009-06-16       Impact factor: 3.397

6.  Incidence and pattern of 12 years of reported transfusion adverse events in Zimbabwe: a retrospective analysis.

Authors:  Nyashadzaishe Mafirakureva; Star Khoza; David A Mvere; McLeod E Chitiyo; Maarten J Postma; Marinus Van Hulst
Journal:  Blood Transfus       Date:  2014-01-02       Impact factor: 3.443

7.  Reporting adverse transfusion reactions: A retrospective study from tertiary care hospital from New Delhi, India.

Authors:  Sangeeta Pahuja; Vandana Puri; Gunjan Mahajan; Prajwala Gupta; Manjula Jain
Journal:  Asian J Transfus Sci       Date:  2017 Jan-Jun

8.  Study of acute transfusion reactions in a teaching hospital of Sikkim: A hemovigilance initiative.

Authors:  Dhruva Kumar Sharma; Supratim Datta; Amlan Gupta
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.